• Jasper Therapeutics received a Nasdaq notice for failing the $1 minimum bid rule after 30 consecutive business days below $1.
• Granted 180 days to regain compliance by Nov. 30, 2026; compliance requires a closing bid of at least $1 for 10 straight sessions.
• Shares and public warrants continue trading on Nasdaq Capital Market under JSPR, JSPRW; no immediate impact on listing.
• Noncompliance by the deadline could trigger delisting risk; a second 180-day cure period may be available, potentially via reverse stock split.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-066782), on June 09, 2026, and is solely responsible for the information contained therein.